Aerin Medical

What Aerin Medical does

Aerin Medical is a privately held, Mountain View, California-based medical device company that develops and commercializes temperature-controlled radiofrequency (RF) systems for non-invasive, office-based treatment of chronic nasal conditions. The company's product platform centers on the Aerin Console, a compact touch-screen generator that pairs with interchangeable single-use styli: the VivAer Stylus for nasal airway obstruction (remodeling soft tissue and cartilage of the nasal valve, inferior turbinate, and septal swell body) and the RhinAer / next-generation RhinAer+ Stylus for chronic rhinitis (disrupting the posterior nasal nerve). Both procedures are performed in the physician office under local anesthesia, are incisionless, and target large U.S. patient populations — approximately 20 million NAO sufferers, 30 million non-allergic rhinitis sufferers, and 60 million allergic rhinitis sufferers.

Aerin's business model is hardware-driven B2B sales of capital (console) and consumable (stylus) devices to ENT physicians and otolaryngology practices, supported by a dedicated direct field sales force, a Find-a-Doctor locator that funnels patients to trained providers, and a multi-channel marketing program spanning medical conferences, peer-reviewed clinical publications, and direct-to-patient social media. Revenue is supplemented — not yet quantified publicly — by an increasingly favorable reimbursement stack: dedicated Category I CPT codes for nasal valve repair (effective Jan 2023) and endoscopic posterior nasal nerve ablation (effective Sept 2025), CMS-set payment rates, Medicare Advantage coverage from UnitedHealthcare, and Cigna commercial coverage (Sept 2025) covering 15M+ lives.

The company is backed by a syndicate of healthcare-specialist growth investors (Ally Bridge Group, KCK MedTech, Questa Capital, OrbiMed, and Ares Management Credit funds) that have together provided over $165 million in disclosed equity and debt financing since 2018. Aerin holds an extensive U.S. patent portfolio exceeding 40 issued patents covering both NAO and rhinitis indications and the console hardware, with international patents pending. The company has cumulatively treated more than 200,000 patients with VivAer and RhinAer as of March 2026 and currently sells only in the United States.

Name

Aerin Medical

Legal name

Aerin Medical Inc.

Website

http://www.aerinmedical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Aerin Medical generates revenue through the sale of its proprietary medical devices - VivAer Stylus and RhinAer Stylus - along with the Aerin Console. These devices are sold to ENT physicians for use in office-based procedures treating nasal airway obstruction and chronic rhinitis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Aerin Medical develops and manufactures temperature-controlled radiofrequency medical devices for ENT physicians. Its core offerings are the VivAer Stylus (for non-invasive treatment of nasal airway obstruction) and the RhinAer Stylus / RhinAer+ (for treatment of chronic rhinitis), both powered by the Aerin touch-screen Console. The devices enable incisionless, office-based procedures under local anesthesia that remodel soft tissue or disrupt the posterior nasal nerve.

Product overview

Aerin Medical offers a unified portfolio of non-invasive ENT treatment solutions consisting of the VivAer Stylus for nasal airway obstruction and the RhinAer/RhinAer+ Stylus for chronic rhinitis, both powered by the Aerin Console platform. The VivAer and RhinAer styli are handheld radiofrequency devices that physicians use in office settings to treat nasal conditions affecting millions of patients. The compact Aerin touch-screen console delivers temperature-controlled radiofrequency energy through these interchangeable styli, enabling two distinct treatment options from a single platform.

Differentiator

Problem solved

Functional benefit

Brands

• VivAer: Non-invasive treatment for nasal airway obstruction using temperature-controlled radiofrequency technology. The VivAer Stylus delivers precise, tissue-sparing, temperature-controlled RF to treat the nasal valve and related structures.
• RhinAer
• RhinAer+

Products and services

• VivAer Stylus Non-invasive temperature-controlled radiofrequency device that durably remodels soft tissue including cartilage in the nasal valve area, treating lateral wall, inferior turbinate, and septal swell body to relieve nasal airway obstruction. Sold to ENT physicians for in-office use.
• RhinAer Stylus Temperature-controlled radiofrequency treatment for chronic rhinitis that disrupts the posterior nasal nerve (PNN), treating runny nose, post-nasal drip, congestion, itching, and sneezing in both allergic and non-allergic rhinitis patients. Sold to ENT physicians.
• RhinAer+ Next-generation minimally invasive treatment for chronic rhinitis with temperature- and impedance-controlled radiofrequency technology targeting the posterior nasal nerve, with improved treatment efficiency and patient comfort compared to the prior RhinAer Stylus.
• Aerin Console

Quantifiable outcome

• 94% responder rate with 69% average improvement in NOSE scores in clinical trials
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Intersect ENT (Medtronic): Intersect ENT, acquired by Medtronic in 2022, developed the PROPEL family of steroid-eluting sinus implants for post-surgical sinus treatment. A direct ENT peer addressing chronic sinusitis with a complementary procedural intervention paradigm.
• Acclarent (Johnson & Johnson): Acclarent, a J&J MedTech business, pioneered balloon sinus dilation and ENT navigation systems. Multiple Aerin executives (Brokaw, Cheng, Ridley, Callister) came from Acclarent, making it a direct comparable in office-based ENT interventional devices.
• Entellus Medical (Stryker): Entellus Medical, acquired by Stryker, developed office-based treatments for nasal and sinus conditions including Latera nasal valve implant and XprESS balloon dilation. Directly comparable to Aerin as an office-based ENT interventional platform serving otolaryngologists, though Stryker's portfolio is broader.

Broad incumbents

• Karl Storz: Karl Storz manufactures rigid endoscopes, instruments, and visualization systems for ENT procedures. An incumbent supplier with overlapping ENT procedure focus but not a direct RF-treatment competitor.
• Medtronic: Medtronic offers ENT and cranial navigation systems, surgical instruments, and post-acquisition of Intersect ENT, sinus implants. A broad medtech incumbent with overlapping ENT capabilities serving otolaryngologists.
• Stryker: Stryker's ENT division (via Entellus acquisition) offers office-based sinus and nasal interventions. A broad incumbent medtech with overlapping but more diversified ENT device portfolio than Aerin.
• Smith+Nephew (Tusker Medical): Smith+Nephew acquired Tusker Medical, which developed in-office treatments for chronic ear conditions. A broader medtech incumbent with an ENT franchise comparable to Aerin's office-based interventional approach.
• Olympus (ENT): Olympus provides ENT endoscopy, imaging, and surgical instrumentation widely used by otolaryngologists. A broad incumbent with overlapping procedure-support products though not a direct procedure competitor.

Emerging players

• HemostODD / SanaVita Medical: Smaller emerging ENT device companies targeting office-based procedures and chronic rhinitis. While not directly named, comparable emerging players in the ENT RF and chronic rhinitis treatment space compete for physician adoption.
• Spirox (acquired by Entellus/J&J): Spirox developed the Latera absorbable nasal valve implant before being acquired into Entellus. Conceptually comparable to Aerin's nasal airway obstruction focus but using an implant approach rather than RF tissue remodeling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AerinMedical
• Facebookfacebook.com/aerinmedical
• LinkedInlinkedin.com/company/aerin-medical
• Instagraminstagram.com/aerinmedical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aerin Medical